Intranasal and Versatope signed agreement to develop universal influenza vaccine based on OMV technology
On Jun. 8, 2020, Intravacc and Versatope announced that they have signed a research service agreement to further develop a universal vaccine against influenza based on Intravaccメs innovative Outer Membrane Vesicles (OMV) technology. Both parties will collaborate to further advance the candidate vaccine through clinical development.
Tags:
Source: Immune Regulation
Credit: